No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 86 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... July 9, 2025 Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs August 12, 2022 Opinion: ‘UK cancer research could be set back years by COVID-19. We must act now’ June 23, 2020 8-Year-Old Cancer Survivor Celebrates Recovery By Donating Her Birthday Gifts To... July 23, 2019 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Trametinib for the Treatment... New on NCI’s Websites for January 2020 Quizartinib Approval Adds New Treatment Option for AML, Including in Older... Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis...
